Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker RANI
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 12, 2026 | RANI Rani Therapeutics Holdings, Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Nov 9, 2026 | RANI Rani Therapeutics Holdings, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 13, 2026 | RANI Rani Therapeutics Holdings, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 4, 2026 | RANI Rani Therapeutics Holdings, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jun 30, 2026 | RANI Rani Therapeutics Holdings, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 29, 2026 | RANI Rani Therapeutics Holdings, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 27, 2026 | RANI Rani Therapeutics Holdings, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| May 15, 2026 | RANI Rani Therapeutics Holdings, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 15, 2026 | RANI Rani Therapeutics Holdings, Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| May 15, 2026 | RANI Rani Therapeutics Holdings, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Mar 26, 2026 | RANI Rani Therapeutics Holdings, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 2, 2026 | RANI Rani Therapeutics Holdings, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jan 2, 2026 | RANI Rani Therapeutics Holdings, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Jan 2, 2026 | RANI Rani Therapeutics Holdings, Inc. | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Jan 2, 2026 | RANI Rani Therapeutics Holdings, Inc. | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 6, 2025 | RANI Rani Therapeutics Holdings, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 27, 2025 | RANI Rani Therapeutics Holdings, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Oct 27, 2025 | RANI Rani Therapeutics Holdings, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Oct 17, 2025 | RANI Rani Therapeutics Holdings, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Oct 17, 2025 | RANI Rani Therapeutics Holdings, Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Oct 17, 2025 | RANI Rani Therapeutics Holdings, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Aug 7, 2025 | RANI Rani Therapeutics Holdings, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 16, 2025 | RANI Rani Therapeutics Holdings, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 26, 2025 | RANI Rani Therapeutics Holdings, Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| May 29, 2025 | RANI Rani Therapeutics Holdings, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 20, 2025 | RANI Rani Therapeutics Holdings, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| May 20, 2025 | RANI Rani Therapeutics Holdings, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| May 13, 2025 | RANI Rani Therapeutics Holdings, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 6, 2025 | RANI Rani Therapeutics Holdings, Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Apr 30, 2025 | RANI Rani Therapeutics Holdings, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Apr 9, 2025 | RANI Rani Therapeutics Holdings, Inc. | 4.01 Changes in Registrant's Certifying Accountant | 8-K | 8-K ↗ |
| Mar 31, 2025 | RANI Rani Therapeutics Holdings, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 14, 2024 | RANI Rani Therapeutics Holdings, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
33 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 4:53 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances